| AL | AS-AQc | DP | Overall |
---|---|---|---|---|
Day 1 | Â | Â | Â | Â |
PPR (%)a | 59.3 % (4,721/7,966) (95 % CI: 52.2–66.3) | 60.3 % (3,463/5,746) (95 % CI: 54.7–65.8) | 59.8 % (1,915/3,204) (95 % CI: 50.3–69.2) | 59.7 % (10,099/16,916) (95 % CI: 54.5–64.9) |
Number of study sitesb | 81 | 52 | 25 | 158 |
Median PPR (IQR; range)b | 61.8 % (35.5–79.1; 0–97.6) | 58.8 % (47.1–77.0; 0.0–96.3) | 53.8 % (32.4–69.4; 18.3–93.0) | 57.9 % (36.1–77.0; 0.0–97.6) |
Day 2 | Â | Â | Â | Â |
PPR (%)a | 5.9Â % (729/12,255) | 7.2Â % (784/10,821) | 7.7Â % (340/4,420) | 6.7Â % (1,853/27,496) |
Number of study sitesb | 100 | 79 | 36 | 215 |
Median PPR (IQR; range)b | 2.9 (1–8.3; 0.0–42.4) | 5.6 % (1.5–12.3; 0.0–88.1) | 3.9 % (0.4–6.7; 0.0–39.1) | 3.3 % (1.2–10.2; 0.0–88.1) |
Day 3 | Â | Â | Â | Â |
PPR (%)a | 0.6Â % (76/13,004) | 1.3Â % (143/11,142) | 0.8Â % (34/4,434) | 0.9Â % (253/28,580) |
Number of study sitesb | 105 | 84 | 36 | 225 |
Median PPR (IQR; range)b | 0.0 % (0.0–0.9; 0.0–7.8) | 0.3 % (0.0–1.6; 0.0–30.7) | 0.0 % (0.0–0.5; 0.0–7.7) | 0.0 % (0.0–0.7;0.0–30.7) |